Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.
You may also be interested in...
Tasigna Approval May Be Again Delayed To Allow FDA Advisory Cmte. Review – Novartis
NDA for next-generation chronic myeloid leukemia therapy currently has late October action date, but FDA may convene ODAC to review Tasigna in December.
Tasigna Approval May Be Again Delayed To Allow FDA Advisory Cmte. Review – Novartis
NDA for next-generation chronic myeloid leukemia therapy currently has late October action date, but FDA may convene ODAC to review Tasigna in December.
Spooling Along: Ariad, Merck Get SPA For Phase III Trial Of Oral Deforolimus
Ariad seeking indication in metastatic soft tissue and bone sarcomas, with progression-free survival primary endpoint.